Peapod Lane Capital LLC Trims Stock Position in Kyverna Therapeutics, Inc. $KYTX

Peapod Lane Capital LLC decreased its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 19.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 318,760 shares of the company’s stock after selling 78,003 shares during the quarter. Kyverna Therapeutics accounts for about 1.7% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 24th largest position. Peapod Lane Capital LLC owned approximately 0.74% of Kyverna Therapeutics worth $1,912,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Phoenix Wealth Advisors purchased a new stake in Kyverna Therapeutics during the second quarter valued at approximately $32,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Kyverna Therapeutics during the 2nd quarter valued at $37,000. Qube Research & Technologies Ltd purchased a new stake in shares of Kyverna Therapeutics in the 2nd quarter worth $43,000. Ethic Inc. bought a new position in Kyverna Therapeutics in the 2nd quarter worth $56,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Kyverna Therapeutics by 25.2% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company’s stock worth $59,000 after purchasing an additional 3,847 shares during the period. 18.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Kyverna Therapeutics

In other news, CTO Karen Marie Walker sold 23,998 shares of Kyverna Therapeutics stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $12.20, for a total value of $292,775.60. Following the sale, the chief technology officer directly owned 22,636 shares of the company’s stock, valued at approximately $276,159.20. The trade was a 51.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Beth C. Seidenberg bought 133,333 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average price of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the transaction, the director directly owned 869,317 shares of the company’s stock, valued at $6,519,877.50. This represents a 18.12% increase in their position. The disclosure for this purchase is available in the SEC filing.

Kyverna Therapeutics Price Performance

Kyverna Therapeutics stock opened at $7.68 on Monday. Kyverna Therapeutics, Inc. has a 1 year low of $1.78 and a 1 year high of $13.67. The firm’s 50 day moving average price is $8.47 and its 200-day moving average price is $6.80. The stock has a market cap of $336.38 million, a P/E ratio of -2.06 and a beta of 3.45.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on KYTX. HC Wainwright raised their price objective on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Wells Fargo & Company lifted their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, December 29th. Finally, Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kyverna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.67.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.